Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.41 |
| ▸ | RARG | P13631 | 2/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8776387 | 0.95 | RARB (0.44) | RARBRARGRARARXRATRPA1 | |
| SCHEMBL15082353 | 0.90 | RARB (0.41) | RARBRARGRARARXRATRPA1 | |
| SCHEMBL1717831 | 0.81 | TRPA1 (0.41) | TRPA1 | |
| SCHEMBL5442565 | 0.81 | RARB (0.37) | RARBRARGRARARXRATRPA1 | |
| SCHEMBL5441832 | 0.79 | TRPA1 (0.40) | RARBRARGRARARXRATRPA1 | |
| SCHEMBL5441829 | 0.79 | TRPA1 (0.40) | RARBRARGRARARXRATRPA1 | |
| SCHEMBL21574083 | 0.79 | MEN1 (0.46) | RARBRARGRARARXRATRPA1 | |
| SCHEMBL20568513 | 0.79 | TRPA1 (0.36) | RARBRARGRARARXRATRPA1 | |
| SCHEMBL15435465 | 0.79 | ALDH1A1 (0.38) | RARBRARGRARARXRATRPA1 | |
| SCHEMBL3411784 | 0.79 | POLB (0.36) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673898-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | Nitto Denko Corporation (JP) | 2020-07-01 | — | — | EP | claimed |
| EP-2773326-B1 | METHOD FOR STERILELY PRODUCING LIPID-NUCLEIC ACID PARTICLES | NITTO DENKO CORP (JP) | 2019-02-20 | — | — | EP | claimed |
| US-10155945-B2 | Method of producing lipid nanoparticles for drug delivery | NITTO DENKO CORPORATION (JP) | 2018-12-18 | — | — | US | claimed |
| US-20170152516-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | NITTO DENKO CORPORATION (JP) | 2017-06-01 | — | — | US | claimed |
| EP-3673898-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | Nitto Denko Corporation (JP) | 2020-07-01 | — | — | EP | disclosed |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2020-06-02 | — | — | US | disclosed |
| EP-2998289-B1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORP (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-3485875-A1 | SINGLE USE SYSTEM FOR STERELILY PRODUCING LIPID-NUCLEIC ACID PARTICLES | Nitto Denko Corporation (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2773326-B1 | METHOD FOR STERILELY PRODUCING LIPID-NUCLEIC ACID PARTICLES | NITTO DENKO CORP (JP) | 2019-02-20 | — | — | EP | disclosed |
| US-10196637-B2 | Retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10155945-B2 | Method of producing lipid nanoparticles for drug delivery | NITTO DENKO CORPORATION (JP) | 2018-12-18 | — | — | US | disclosed |
| US-20180297938-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP | 2018-10-18 | — | — | US | disclosed |
| WO-2012170952-A9 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012170952-A9 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
| WO-2012170952-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170952-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
| US-20100168045-A1 | Novel Polyunsaturated Compounds, Method for Preparing Same and Compositions Containing the Same | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168045-A1 | Novel Polyunsaturated Compounds, Method for Preparing Same and Compositions Containing the Same | CBR3, CBR1, DECR1 | RARB 730/4885RARG 442/4885RARA 469/4885 |
| US-20180297938-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | RARB 8/4885RARG 2/4885RARA 4/4885 |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | RARB 8/4885RARG 2/4885RARA 4/4885 |
| US-20170152516-A1 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | PHOSPHO1, LIPA, LIPC | RARB 3217/4885RARG 2158/4885RARA 2152/4885 |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | RARB 8/4885RARG 2/4885RARA 4/4885 |
| US-10155945-B2 | Method of producing lipid nanoparticles for drug delivery | PHOSPHO1, LIPA, LIPC | RARB 3217/4885RARG 2158/4885RARA 2152/4885 |
| US-10196637-B2 | Retinoid-lipid drug carrier | RXRA, RXRG, LRAT | RARB 8/4885RARG 10/4885RARA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.